News: Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

76.60EUR
11:35am EDT
Price Change (% chg)

€-0.45 (-0.58%)
Prev Close
€77.05
Open
€77.40
Day's High
€77.42
Day's Low
€76.28
Volume
2,728,755
Avg. Vol
2,878,905
52-wk High
€87.03
52-wk Low
€68.29

Search Stocks
Select another date:

Mon, Apr 7 2014

Sanofi to resubmit Lemtrada application for FDA review

PARIS, April 7 - Sanofi said it plans to resubmit its application for its Lemtrada drug for the treatment of relapsing forms of multiple sclerosis following "constructive discussions" with the U.S. Food and Drug Administration.

Sanofi eyes more acquisitions, sees growth in Africa

PARIS - Sanofi is on the lookout for acquisitions to boost key business units, such as consumer and animal health products, and expects strong growth in the "strategic continent" of Africa, its chief executive told Reuters on Wednesday.

Sanofi faces make-or-break verdict on big dengue vaccine bet

NEUVILLE-SUR-SAONE, France - Sanofi expects final clinical results for its vaccine against dengue by late September, the French drugmaker's project leader has told Reuters, and has already gambled on starting production despite some disappointing early trials data.

Sanofi faces make-or-break verdict on big dengue vaccine bet

* Sales could top 1 bln euros but project is risky -analysts

Sanofi teams up with South Korean group on pneumococcal vaccine

PARIS - French drugmaker Sanofi said its Sanofi Pasteur unit had signed a long-term cooperation deal with South Korea's SK Chemical Co to develop and market a vaccine against pneumococcal infection.

Sanofi teams up with South Korean group on pneumococcal vaccine

PARIS, March 19 - French drugmaker Sanofi said its Sanofi Pasteur unit had signed a long-term cooperation deal with South Korea's SK Chemical Co to develop and market a vaccine against pneumococcal infection.

Rivals race to develop new biotech asthma drugs

* GSK leads new wave with mepolizumab due for 2014 filing

Sanofi, UCB set up drug development partnership

PARIS - French and Belgian drugmakers Sanofi and UCB have entered a partnership aimed at finding treatments for so-called immune-mediated diseases in areas such as rheumatoid arthritis and inflammatory bowel conditions.

Sanofi, UCB set up drug development partnership

PARIS, March 11 - French and Belgian drugmakers Sanofi and UCB have entered a partnership aimed at finding treatments for so-called immune-mediated diseases in areas such as rheumatoid arthritis and inflammatory bowel conditions.

FDA probes cognitive impact of new cholesterol drugs

- The Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday.

Select another date:
Search Stocks